Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;14(2):134-145.
doi: 10.1007/s11897-017-0327-y.

Potential Expanded Indications for Neprilysin Inhibitors

Elizabeth Riddell  1 , Justin M Vader  2
Affiliations
Review

Potential Expanded Indications for Neprilysin Inhibitors

Elizabeth Riddell et al. Curr Heart Fail Rep. 2017 Apr.

Abstract

Purpose of review: The goal of this article is to review potential expanded indications for neprilysin inhibitors. This article reviews the rationale and design for ongoing and future trials of sacubitril/valsartan in cardiovascular and non-cardiovascular disease.

Recent findings: Randomized trial data are lacking for use of sacubitril/valsartan in acute heart failure and advanced heart failure. Mechanistic data from animal studies suggest a role for neprilysin inhibition in the treatment of post-myocardial infarction systolic dysfunction and heart failure with preserved ejection fraction. Beyond the cardiovascular system, renal and neurological function may be impacted by neprilysin inhibition. Forthcoming randomized trials will address the clinical impact of sacubitril/valsartan on these conditions. Neprilysin inhibition with sacubitril/valsartan offers a new therapeutic strategy with a broad range of potential therapeutic actions. In PARADIGM-HF, the combination of neprilysin and RAAS inhibition was proven to be superior to enalapril for patients with stable NYHA class II-III heart failure and reduced left ventricular ejection fraction. Preliminary data suggests it may also have a role in other cardiovascular and non-cardiovascular disease. Several ongoing and planned studies will determine the extent of its benefit for these other indications.

Keywords: Cardiovascular disease; Heart failure; Neprilysin inhibitors; Sacubitril/valsartan.

PubMed Disclaimer

References

    1. Teerlink JR, Bourge RC, Cleland JGF, Jondeau G, Krum H, Metra M, Connor CMO, Parker JD, Lewsey J, Frey A, Rainisio M. Effects of Tezosentan on Symptoms. Heart Fail. 2009;298:2009–2019. - PubMed
    1. Prasad SK, Dargie HJ, Smith GC, Barlow MM, Grothues F, Groenning BA, Cleland JGF, Pennell DJ. Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study. Heart [Internet] 2006;92:798–803. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16339819%5Cnhttp://www.pubmedcentral..... - PMC - PubMed
    1. Anand PI, McMurray PJ, Cohn PJN, Konstam PMA, Notter T, Quitzau K, Ruschitzka F, L??scher PTF. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): Randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:347–354. - PubMed
    1. Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, Van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted Anticytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) Circulation. 2004;109:1594–1602. - PubMed
    1. McMurray JJV, Krum H, Abraham WT, Dickstein K, Køber LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM ATMOSPHERE Committees Investigators. Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med [Internet] 2016;374:1521–32. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1514859%5Cnhttp://www.ncbi.nlm.nih.... - DOI - PubMed